JenKem Technology Co., Ltd.
5 clinical trials · Sponsor
◉ Watch JenKem Technology Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases (NCT06586866) | JenKem Technology Co., Ltd. | 2024-09-26 |
| JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) (NCT06595186) | JenKem Technology Co., Ltd. | 2022-10-31 |
| Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC (NCT05158491) | JenKem Technology Co., Ltd. | 2021-11-11 |
| Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor (NCT04366648) | JenKem Technology Co., Ltd. | 2018-05-04 |
Track JenKem Technology Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.